APPENDIX 2. PEER REVIEWER INFORMATION 2021 UPDATE TO THE 2017 ACC EXPERT CONSENSUS DECISION PATHWAY FOR OPTIMIZATION OF HEART FAILURE TREATMENT: ANSWERS TO 10 PIVOTAL ISSUES ABOUT HEART FAILURE WITH REDUCED EJECTION FRACTION This table represents the individuals, organizations, and groups that peer-reviewed this document. A list of corre- sponding comprehensive healthcare-related disclosures for each reviewer is available in a Supplemental Appendix 3. J Maddox et al. APPENDIX 3. ABBREVIATIONS ACC American College of Cardiology ACEI angiotensin-converting enzyme inhibitor AF atrial brillation AHA American Heart Association ARB angiotensin receptor blocker ARNI angiotensin receptor-neprilysin inhibitor BNP B-type natriuretic peptide CI con dence interval COVID-19 coronavirus disease 2019 CV cardiovascular ECDP expert consensus decision pathway EF ejection fraction eGFR estimated glomerular ltration rate GDMT guideline-directed medical therapy HF heart failure HFrEF heart failure with reduced ejection fraction HFSA Heart Failure Society of America HYD/ISDN hydralazine/isosorbide dinitrate LV left ventricular LVEF left ventricular ejection fraction MR mitral regurgitation NT-proBNP N-terminal pro B-type natriuretic peptide NYHA New York Heart Association RWI relationships with industry SSOC Solution Set Oversight Committee T2D type 2 diabetes Maddox et al. J